{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:39Z","timestamp":1787962299781,"version":"build-2784847793"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T00:00:00Z","timestamp":1524614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0196210","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T13:41:43Z","timestamp":1524663703000},"page":"e0196210","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-5331","authenticated-orcid":true,"given":"Ying-Ming","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Shu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Arnold","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,4,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrrheum.2010.214","article-title":"Hepatotoxicity related to antirheumatic drugs","volume":"7","author":"GP Aithal","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"JR Curtis","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref3","first-page":"363","article-title":"Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis","volume":"18","author":"M Mok","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10620-006-9074-8","article-title":"Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents","volume":"51","author":"F Tsai","year":"2006","journal-title":"Dig Dis Sci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10067-012-1988-2","article-title":"Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs","volume":"31","author":"J Tan","year":"2012","journal-title":"Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3899\/jrheum.110289","article-title":"Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases","volume":"38","author":"M Kato","year":"2011","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Hepatitis B virus infection","volume":"337","author":"WM Lee","year":"1997","journal-title":"N Engl J Med"},{"key":"ref8","first-page":"1","article-title":"Epidemiological study on hepatitis B virus infection in Taiwan","volume":"1","author":"JL Sung","year":"1984","journal-title":"Chin J Gastroenterol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0929-6646(09)60231-X","article-title":"Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants","volume":"106","author":"CH Chen","year":"2007","journal-title":"J Formos Med Assoc"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jmv.1890180402","article-title":"Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in Taiwan","volume":"18","author":"HY Hsu","year":"1986","journal-title":"J Med Virol"},{"key":"ref11","first-page":"1","article-title":"Screening and management of hepatitis B infection in rheumatic patients scheduled for biologic therapy: consensus recommendations from the Taiwan Rheumatology Association (Chinese)","volume":"26","author":"YH Chen","year":"2012","journal-title":"Formos J Rheumatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"RP Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00535-016-1168-2","article-title":"Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies","volume":"51","author":"S Mochida","year":"2016","journal-title":"J Gastroenterol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2016-209973","article-title":"Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan","volume":"76","author":"W Fukuda","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref15","first-page":"566","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment","volume":"215","author":"MH Chen","year":"2017","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/0016-5085(95)90694-0","article-title":"Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection","volume":"108","author":"G Marinos","year":"1995","journal-title":"Gastroenterology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/323819a0","article-title":"Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons","volume":"323","author":"GH Wong","year":"1986","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/s10165-010-0337-z","article-title":"Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients","volume":"21","author":"Y Urata","year":"2011","journal-title":"Mod Rheumatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.20130","article-title":"Safety of tumor necrosis factor \u03b1 blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative\/anti-hepatitis B core antigen positive) with rheumatic diseases","volume":"62","author":"R Caporali","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref20","first-page":"780","article-title":"Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus","volume":"38","author":"C Geannitti","year":"2011"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3109\/s10165-011-0458-z","article-title":"Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and\/or nonbiological disease-modifying antirheumatic drugs","volume":"21","author":"S Mori","year":"2011","journal-title":"Mod Rheumatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1756-185X.12359","article-title":"Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"19","author":"J Nakamura","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/ard.2010.148783","article-title":"Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy","volume":"70","author":"JL Lan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ibd.20035","article-title":"Occult hepatitis B and infliximab-induced HBV reactivation","volume":"13","author":"S Madonia","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1478-3231.2010.02238.x","article-title":"Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection","volume":"30","author":"T Matsumoto","year":"2010","journal-title":"Liver Int"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/14712598.2012.646986","article-title":"Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management","volume":"12","author":"M Vigan\u00f2","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"R P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3899\/jrheum.081324","article-title":"Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy","volume":"36","author":"SJ Chung","year":"2009","journal-title":"J Rheumatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1346-8138.2011.01434.x","article-title":"Use of anti-tumor necrosis factor-\u03b1 therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan","volume":"39","author":"YT Cho","year":"2012","journal-title":"J Dermatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10067-012-1960-1","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF\u03b1 agents: a retrospective analysis of 49 cases","volume":"31","author":"HH Ryu","year":"2012","journal-title":"Clin Rheumatol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/ard.2009.112136","article-title":"CORRONA Investigators. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis","volume":"69","author":"J Sokolove","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref32","first-page":"258","article-title":"Modern Epidemiology","author":"S Greenland","year":"2008"},{"key":"ref33","first-page":"118","article-title":"Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy","volume":"31","author":"YH Lee","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","author":"RP Perrillo","year":"2001","journal-title":"Gastroenterology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(02)00773-8","article-title":"Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue","volume":"3","author":"S Vento","year":"2002","journal-title":"Lancet Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0196210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T12:10:23Z","timestamp":1540037423000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0196210"}},"subtitle":[],"editor":[{"given":"Chiaho","family":"Shih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,25]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0196210","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,25]]}}}